PNAS published February 23, 2004. 101 (9) 2806-2810
CIS display: In vitro selection of peptides from libraries of protein–DNA complexes
read more
Technical Resources
A selection of technical resources.
The structure of myeloid cell-specific TNF inhibitors affects their biological properties
Immunogenicity and humanization of single-domain antibodies
Nature publication: AAV delivery of VHH Intrabodies
De Genst et al showcase the AAV delivery and intracellular in vivo expression of Isogenica’s LlamdA™ VHHs in monomeric and bivalent forms. Interestingly, these VHHs display preferences for distinct...
Optimizing CAR-T and T-cell antibody engagers in haematological and solid tumours
A role for VHH single domain antibodies.
Isogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its...
Isogenica ISOXTEND® half-life extension for biotherapeutics
Our VHH-based ISOXTEND® technology protects biotherapeutics from kidney clearance by ‘piggybacking’ onto the serum albumin endocytic recycling pathway, significantly extending therapeutic...
COLIBRA®
CODON-PRECISE, SYNTHETIC, ANTIBODY FRAGMENT LIBRARIES BUILT USING AUTOMATED HEXAMER CODON ADDITIONS AND VALIDATED THROUGH NEXT GEN SEQUENCING Antibodies 2015, 4(2), 88-102
Review: Immunogenicity Risk Profile of Nanobodies
Ackaert et al review the immunogenicity risk profile of two VHHs from Phase II clinical trials, examining pre-existing ADAs and comparing to 3 months post-administration.
LlamdA®
ANTI-LRP5/6 VHHS promote differentiation of WNT-hypersensitive intestinal stem cells Nature Communications 2019 10 (365)
Review: The Application of Nanobody in CAR-T Therapy
Bao et al review the intersection between CAR-T development and VHHs against over a dozen tumour-associated antigens, with a focus on the bi-specific VHH therapy LCAR-B38M, now approved as CARVYKTI™.
VHHs enable multi-specific targeting for Tandem-CAR therapies
In this poster from 7th CAR-TCR Summit in Boston, we discuss the power of VHHs in creating multi-specific ectodomains.